Title |
胃癌Nivolumab療法において癌病態とともに血清可溶性IL-2受容体/リンパ球数比(sIL-2R/Ly数比)が推移した1例
|
---|---|
Published in |
Nippon Shokakibyo Gakkai zasshi The Japanese journal of gastro-enterology, August 2021
|
DOI | 10.11405/nisshoshi.118.768 |
Pubmed ID | |
Authors |
Marina Masui, Yuko Tamura, Takuto Funatsuya, Yoshiro Fujii, Masazumi Takahashi |
Abstract |
A 90-year-old woman diagnosed with stage IV gastric cancer (pT4a[SE]N2M1 [P, CY1]) after distal gastrectomy for her tarry stool was treated with S-1 monotherapy for 7 months, nab-PTX monotherapy for 3 months, and wPTX+RAM therapy for 3 months. Ascending colon tumor was revealed as peritoneal recurrence treated via right hemicolectomy. The nivolumab therapy was started as the fourth treatment. As the tumor progressed, sIL-2R, a destruction product of regulatory T cell surface antigens, tended to increase and the lymphocyte count tended to decrease, with the sIL-2R/lymphocyte count ratio changing in parallel with CA19-9. Throughout the course after gastrectomy, NLR increased and LMR decreased as the tumor status and general condition worsened. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 1 | 50% |
Unknown | 1 | 50% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 1 | 50% |
Unknown | 1 | 50% |